Navigation Links
Salugen to Present at Nutrition Capital Network's First In-Person Investor Meeting
Date:10/9/2007

Nutrigenomic Company to Present Unique Business Model

SAN DIEGO, Oct. 9 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company and recent consecutive year award winner from the Natural Products Association for its nutritional genetic research, announces today that it has been selected to present at the first annual Nutrition Capital Network investor meeting, October 17, 2007 in San Francisco, CA.

Presenting companies are pre-screened by the Nutrition Capital Network institutional investors for their uniqueness and protectibility of their product or service; strength of business model; experience of the management team and the caliber of the investment proposal. Investors attending this meeting include: The Dannon Company, DuPont, Nestle, PHYSIC Ventures, Rosewood Capital, North Castle Partners, Sherbrooke Capital, Burrill & Co, and many others.

Salugen CEO Brian Meshkin states, "We are honored to present Salugen's unique business to the investment community attending the Nutrition Capital Network inaugural meeting. Salugen's technology has been scientifically and clinically validated by our extensive compilation of peer-reviewed publications, years of research, record of clinical studies, and extensive intellectual property that sets us apart from other companies involved in nutrigenomics. We look forward to the opportunity of sharing our vision with strategic investor partners at the meeting."

Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (http://www.GenoTrim.com), SpaGen (TM) for optimal health and wellness (http://www.SpaGen.com) and Haveos(TM) for substance abuse attenuation.

About Salugen

Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com.


'/>"/>
SOURCE Salugen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... 2017 , ... Many complicated neurological disorders appear to have ... while men are at greater risk for Parkinson’s disease. Understanding some of the ... of a research program at Worcester Polytechnic Institute (WPI) funded by a new ...
(Date:5/16/2017)... , ... May 16, 2017 , ... ... and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a ... cancer, this new test is designed to quickly and accurately identify tumor-related genetic ...
(Date:5/15/2017)... ... May 15, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it has signed an agreement ... support preclinical and clinical development of TA-46, a novel protein addressing achondroplasia, which ...
(Date:5/12/2017)... , May 12, 2017  Eli Lilly and Company ... galcanezumab, an investigational treatment for the prevention of ... in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and ... of monthly migraine headache days compared to placebo ... robust results from these three studies bring us ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
Breaking Biology News(10 mins):